Grail

GRAL · NASDAQ

$124.67+$2.25 (+1.84%)TodayMarket closed · Oct 20, 7:46 PM ET

Prev close $122.42

GRAL analyst rating

BuyConsensus of 10 analysts over the last 12 months. 50% rate it a buy.

Strong buy0
Buy5
Hold5
Underperform0
Sell0

12-month price target · 12 analysts

Average $99.35 (−20.3% downside)

Low: $60.60
Now: $124.67
High: $157.50

Upgrades and downgrades

The latest rating actions, newest first

GRAL analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Morgan Stanley	Oct 13, 2026	Maintains	Equal-Weight	$60.00 → $120.00	48%
TD Cowen	Oct 13, 2026	Maintains	Buy	$88.00 → $180.00	61%
UBS	Oct 2, 2026	Maintains	Buy	$105.00 → $175.00	59%
Guggenheim	Oct 1, 2026	Maintains	Buy	$75.00 → $155.00	66%
Canaccord Genuity	Sep 28, 2026	Maintains	Buy	$80.00 → $150.00	55%
Mizuho	Sep 25, 2026	Maintains	Neutral	$65.00 → $100.00	100%
Baird	Sep 22, 2026	Maintains	Outperform	$96.00 → $118.00	61%
RBC Capital	Sep 17, 2026	Initiates	Sector Perform	$84.00	59%
UBS	Sep 9, 2026	Initiates	Buy	$105.00	59%
Mizuho	Jul 15, 2026	Maintains	Neutral	$58.00 → $65.00	100%

The case for and against

Updated Oct 16, 2026

Bull case

GRAIL is supported by a differentiated clinical profile for Galleri, with studies showing 99.6% specificity, over 90% cancer signal origin accuracy, 60% positive-predictive value in PATHFINDER 2, and a 14% reduction in Stage IV cancers in NHS-Galleri. Its extensive dataset, including over 300K tests in studies and trials, strengthens the case for FDA approval and helps position the test as a potential gold standard in a large, underpenetrated MCED market. Near-term catalysts such as FDA approval, Medicare coverage, and broader guideline adoption could unlock stronger revenue growth, while 1Q revenue of $40.8M, 28% total sales growth, and $823M in cash underscore improving commercial momentum.

Bear case

GRAIL is viewed negatively because it has incurred significant net losses since inception and is expected to keep burning cash while funding lengthy, expensive clinical studies, regulatory filings, and commercialization efforts that may require additional financing. Its Galleri test faces major adoption hurdles: FDA has never approved an MCED test, broader government reimbursement is not yet in place, and the self-pay market at a $949 cash-pay price appears structurally limited with weak conversion even among affluent, health-motivated patients. On top of that, the company depends on sole suppliers, limited third-party service providers, and may face rising costs as the Illumina royalty resumes in 2027, leaving upside constrained by slow volume growth and continued OpEx above revenue.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.